TP53 and acute myeloid leukemia: In this pathway, different kinds of mutations decide the progression fate: “type 1 mutations” cause the transformation from MDS to AML, and “type 2 mutations,” that include TP53, favor the progression from lower-risk to higher-risk MDS [42].